View Older Stories View More Recent Stories
-
Rexel : Erratum to the Press release Q4 sales & FY 2025 results
-
Michelin delivered segment operating income of €2.9 billion in 2025, at constant exchange rates. The Group generated high free cash flow before M&A of €2.1 billion and strengthened its financial
-
Rexel: Q4 sales & FY 2025 result
-
Rexel: Q4 sales & FY 2025 result
-
Spotify (SPOT) PT Lowered to $525 at Cantor Fitzgerald Given Premium Valuation
-
Worksport reports 65% revenue growth in fourth quarter
-
Worksport Delivers Breakout Q4: Revenue Up 65% YoY, Gross Profit Up 380%
-
Spotify (SPOT) PT Raised to $514 at MoffettNathanson
-
Shopify issues upbeat quarterly forecasts, $2 billion stock buyback plan
-
Kraft Heinz pauses split, new CEO says problems are 'fixable'
-
Healthcare Services Group Reports Full Year and Fourth Quarter Results
-
Spotify (SPOT) PT Lowered to $720 at Guggenheim
-
Smurfit Westrock sets $7 billion EBITDA target by 2030
-
Smurfit Westrock Medium-Term Investor Update
-
Micron Technology (MU) PT Raised to $450 at Morgan Stanley
-
Spotify (SPOT) PT Lowered to $650 at Morgan Stanley, Named New Top Pick
-
Fiserv (FISV) PT Lowered to $64 at Morgan Stanley
-
Spotify (SPOT) PT Lowered to $750 at BofA Securities
-
T-Mobile Q4 earnings and investor day preview: soft profit expected, outlook in focus
-
Ralph Lauren debuts its fall 2026 collection ahead of New York Fashion Week
-
Spotify (SPOT) PT Lowered to $670 at Goldman Sachs
-
Genasys Reports Fiscal First Quarter 2026 Results
-
Electromed, Inc. Announces Record Financial Performance in Fiscal 2026 Second Quarter
-
Klaviyo Delivers Outstanding 2025 Results: 32% Revenue Growth, Record Fourth Quarter and Raised Fiscal Year 2026 Outlook
-
Spotify (SPOT) PT Lowered to $650 at Jefferies
-
Spotify (SPOT) PT Lowered to $750 at Canaccord Genuity
-
MedImpact Offers Humira Biosimilar 95% Below the Cost of Humira to Any Hospital or Pharmacy
-
MedImpact Offers Humira Biosimilar 95% Below the Cost of Humira to Any Hospital or Pharmacy
-
The American Customer Satisfaction Index (ACSI): Quarter 4, 2025
-
Apple (AAPL) PT Raised to $340 at Bernstein SocGen Group
-
Coca-Cola's incoming CEO seeks faster innovation as low-sugar, weight-loss trends grow
-
Energy Exchange ElectronX Launches First Direct-Access U.S. Power Derivatives For Intraday Volatility
-
Entegris Reports Results for Fourth Quarter of 2025
-
Harley-Davidson Delivers Fourth Quarter and Full Year Financial Results and 2026 Outlook
-
Simpson Manufacturing (SSD) PT Raised to $200 at Stephens
-
S&P 500, Nasdaq dip with economic data, earnings in focus
-
Spotify forecasts profit above estimates as founder Daniel Ek moves to new role
-
RBC Capital Downgrades Amotiv Ltd (AOV:AU) to Sector Perform
-
Goldman Sachs Double Upgrades Evonik Industries AG (EVK:GR) (EVKIF) to Buy
-
Spotify earnings preview Q4: strong print expected on robust user growth; margins in focus
-
Kering shares surge as De Meo flags Gucci-owner's 'fragile' revival
-
Celanese Announces Acetic Acid, Vinyl Acetate Monomer (VAM) and Derivatives Price Increases in the Western Hemisphere
-
Friedman Industries, Incorporated Announces Third Quarter Results
-
Cincinnati Financial Reports Fourth-Quarter and Full-Year 2025 Results
-
EVI Industries Reports Record Second Quarter Results
-
Jefferies says Steve Madden growth faces pressure as wholesale headwinds build
-
Survey: Business Owners Shoulder Rising Costs to Protect Workers
-
Mexico inflation speeds up in January after new taxes go into effect
-
Americans Automate Spending as Retirement Falls Out of Reach, Finds PensionBee
-
Behind the "Black Box;" As 2026 Rx Price Hikes Emerge, SHARx Exposes Specialty Drug Pricing
